<small id='uf6de'></small><noframes id='uf6de'>

  • <tfoot id='uf6de'></tfoot>

      <legend id='uf6de'><style id='uf6de'><dir id='uf6de'><q id='uf6de'></q></dir></style></legend>
      <i id='uf6de'><tr id='uf6de'><dt id='uf6de'><q id='uf6de'><span id='uf6de'><b id='uf6de'><form id='uf6de'><ins id='uf6de'></ins><ul id='uf6de'></ul><sub id='uf6de'></sub></form><legend id='uf6de'></legend><bdo id='uf6de'><pre id='uf6de'><center id='uf6de'></center></pre></bdo></b><th id='uf6de'></th></span></q></dt></tr></i><div id='uf6de'><tfoot id='uf6de'></tfoot><dl id='uf6de'><fieldset id='uf6de'></fieldset></dl></div>

          <bdo id='uf6de'></bdo><ul id='uf6de'></ul>

          1. <li id='uf6de'><abbr id='uf6de'></abbr></li>
          2.  
             
            当前地位: edf壹定发888 » 材料 » 医药中心体库 » ,C19H28N4O6,408.4582,(2S)-5-[(Amino[[(benzyloxy)carbonyl]imi

            ,C19H28N4O6,408.4582,(2S)-5-[(Amino[[(benzyloxy)carbonyl]imi

            放大年夜字体  缩小字体 更新日期:2018-05-06  浏览次数:7
            壹定发老虎机娱乐平台:,C19H28N4O6,408.4582,(2S)-5-[(Amino[[(benzyloxy)carbonyl]imino]methyl)amino]-2-[(tert-butoxycarbonyl)amino]pentanoic acid
            • 【化学名】(2S)-5-[(Amino[[(benzyloxy)carbonyl]imino]methyl)amino]-2-[(tert-butoxycarbonyl)amino]pentanoic acid
            • 【CAS挂号号】
            • 【构造式】,C19H28N4O6,408.4582,(2S)-5-[(Amino[[(benzyloxy)carbonyl]imi--药物合成数据库
            • 【份子式】C19H28N4O6
            • 【份子量】408.4582
            • 【来源】
            • 【合成情况】 
            • 〖目标产品〗Efegatran sulfate hydrate, LY-294468, GYKI-14766
            • 〖合成线路〗
            • 〖合成办法〗The synthesis of GYKI-14766 is as follows: N2-tert-Butoxycarbonyl-L-arginine (I) was converted to the N6-benzyloxycarbonyl derivative (II). Treatment of (II) with isobutoxycarbonyl chloride and N-methylmorpholine gave the aminolactam (III). Dicyclohexylcarbodiimide-mediated esterification of N-benzyloxycarbonyl-D-phenylalanine (IV) with 2,4,5-trichlorophenol gave the active ester (V), which was coupled with L-proline to the dipeptide (VI). Methylation with iodomethane afforded the N-methyl derivative isolated as the cyclohexylamine salt (VII). The fragments (III) and (VII) were coupled via the mixed anhydride of (VII), generated as in the case of (II), giving the tripeptide lactam (VIII). Reduction with lithium aluminum hydride at low temperature converted (VIII) to the aldehyde (IX), which was finally deprotected to the end product.
            • 〖参考〗Szll, E.; Bagdy, D.; Bajusz, S.; et al.; Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation and its stable N-methyl derivative, D-MePhe-Pro-Arg-H. J Med Chem 1990, 33, 6, 1729-35
            • 〖目标产品〗Efegatran sulfate hydrate, LY-294468, GYKI-14766
            • 〖合成线路〗
            • 〖合成办法〗The synthesis of GYKI-14766 is as follows: N2-tert-Butoxycarbonyl-L-arginine (I) was converted to the N6-benzyloxycarbonyl derivative (II). Treatment of (II) with isobutoxycarbonyl chloride and N-methylmorpholine gave the aminolactam (III). Dicyclohexylcarbodiimide-mediated esterification of N-benzyloxycarbonyl-D-phenylalanine (IV) with 2,4,5-trichlorophenol gave the active ester (V), which was coupled with L-proline to the dipeptide (VI). Methylation with iodomethane afforded the N-methyl derivative isolated as the cyclohexylamine salt (VII). The fragments (III) and (VII) were coupled via the mixed anhydride of (VII), generated as in the case of (II), giving the tripeptide lactam (VIII). Reduction with lithium aluminum hydride at low temperature converted (VIII) to the aldehyde (IX), which was finally deprotected to the end product.
            • 〖参考〗Ngradi, M.; GYKI-14766. Drugs Fut 1992, 17, 12, 1087
            • 〖目标产品〗
            • 〖合成线路〗
            • 〖合成办法〗Solution-phase synthesis: Protection of the side-chain of Boc-Arg-OH (IX) by treatment with Cbz-Cl in aqueous NaHCO3 yields Boc-Arg(Cbz)-OH (X), which is then converted into arginine lactam (XI) by a first treatment with isobutyl chloroformate (i-BuO2CCl) and NMM in THF followed by Boc deprotection with HCl/dioxane. Condensation of N-deprotected lactam (XI) with protected dipeptide (XII) by means of BOP/DIEA in DMF provides the tripeptide lactam (XIII), which is finally reduced with LiAlH4 in THF and hydrogenated over Pd/C for protecting group removal.
            • 〖参考〗Marlowe, C.K.; Sinha, U.; Scarborough, R.M.; Gunn, A.C.; Design, synthesis and structure-activity relationship of a series of arginine aldehyde factor Xa inhibitors. Part 1: Structures based on the (D)-Arg-Gly-Arg tripeptide sequence. Bioorg Med Chem Lettg=http://www.che
            • 〖目标产品〗
            • 〖合成线路〗
            • 〖合成办法〗Solution-phase synthesis: Protection of the side-chain of Boc-Arg-OH (IX) by treatment with Cbz-Cl in aqueous NaHCO3 yields Boc-Arg(Cbz)-OH (X), which is then converted into arginine lactam (XI) by a first treatment with isobutyl chloroformate (i-BuO2CCl) and NMM in THF followed by Boc deprotection with HCl/dioxane. Condensation of N-deprotected lactam (XI) with protected dipeptide (XII) by means of BOP/DIEA in DMF provides the tripeptide lactam (XIII), which is finally reduced with LiAlH4 in THF and hydrogenated over Pd/C for protecting group removal.
            • 〖参考〗Marlowe, C.K.; Scarborough, R.M.; Laibelman, A.M.; Sinha, U.; Zhu, B.-Y. (COR Therapeutics, Inc.); Inhibitors of factor Xa. EP 0846125; JP 1999507626; US 5919765; WO 9640743
            • 〖目标产品〗
            • 〖合成线路〗
            • 〖合成办法〗Solution-phase synthesis: Protection of the side-chain of Boc-Arg-OH (IX) by treatment with Cbz-Cl in aqueous NaHCO3 yields Boc-Arg(Cbz)-OH (X), which is then converted into arginine lactam (XI) by a first treatment with isobutyl chloroformate (i-BuO2CCl) and NMM in THF followed by Boc deprotection with HCl/dioxane. Condensation of N-deprotected lactam (XI) with protected dipeptide (XII) by means of BOP/DIEA in DMF provides the tripeptide lactam (XIII), which is finally reduced with LiAlH4 in THF and hydrogenated over Pd/C for protecting group removal.
            • 〖参考〗Marlowe, C.K.; Scarborough, R.M.; Laibelman, A.M.; Sinha, U.; Zhu, B.-Y. (COR Therapeutics, Inc.); Inhibitors of factor Xa. US 5721214
             
            本文导航:
            • (1) ,C19H28N4O6,408.4582,(2S)-5-[(Amino[[(benzyloxy)carbonyl]imi
            • 下一篇:鳖甲
            • 上一篇:暂无
             
            [ 材料搜刮 ]  [ 参加收藏 ]  [ 告诉石友 ]  [ 打印本文 ]  [ 封闭窗口 ]

             

             
            推荐图文
            推荐材料
            热点存眷